Monique Pouliot, DO
Internal Medicine · Wakefield, RINPI 1285674614
Payments from drug & device makers
Across 174 payments — averaging $21.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$515
- AstraZeneca$462
- Novo Nordisk$446
- Pfizer$430
- Lilly USA, LLC$364
- GSK$238
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,654100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 26 | $515 |
| AstraZeneca | 24 | $462 |
| Novo Nordisk | 20 | $446 |
| Pfizer | 21 | $430 |
| Lilly USA, LLC | 18 | $364 |
| GSK | 12 | $238 |
| Abbott | 8 | $190 |
| Exact Sciences | 6 | $134 |
| Boehringer Ingelheim | 5 | $120 |
| Astellas Pharma US Inc | 4 | $103 |
| Sumitomo Pharma America, Inc. | 4 | $83 |
| Amgen | 3 | $77 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $56 |
| Inspire Medical Systems, Inc. | 2 | $51 |
| Shield Therapeutics Inc | 2 | $46 |
| Scilex Pharmaceuticals Inc. | 1 | $44 |
| Merck | 2 | $42 |
| Johnson & Johnson | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $28 |
| Biogen | 1 | $27 |
| Amarin Pharma, Inc. | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
| Corcept Therapeutics | 1 | $20 |
| Mylan Specialty L.p. | 1 | $19 |
| Emergent Biosolutions Inc. | 1 | $19 |
| Melinta Therapeutics, LLC | 1 | $15 |
| Radius Health, Inc. | 1 | $13 |
How this compares
$3,654 in reported general payments places this provider in the 90th percentile of 808 internal medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 109 | $101,669 |
| EliquisApixaban | 65 | $70,114 |
| JardianceEmpagliflozin | 40 | $37,042 |
| Breo ElliptaFluticasone/Vilanterol | 67 | $35,595 |
| MounjaroTirzepatide | 29 | $29,765 |
| TrulicityDulaglutide | 14 | $13,123 |
| Arnuity ElliptaFluticasone Furoate | 26 | $10,613 |
| MyrbetriqMirabegron | 15 | $8,912 |
| Xtampza ErOxycodone Myristate | 26 | $7,686 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $6,501 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $5,070 |
| Levothyroxine Sodium | 329 | $4,750 |
| Metoprolol Succinate | 201 | $4,662 |
| Atorvastatin Calcium | 422 | $4,513 |
| Omeprazole | 311 | $4,448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $446 | $101,669109 claims |
| PfizerEliquis | $430 | $70,11465 claims |
| GSKBreo Ellipta, Arnuity Ellipta | $238 | $46,20893 claims |
| Lilly USA, LLCMounjaro, Trulicity | $364 | $42,88843 claims |
| Boehringer IngelheimJardiance | $120 | $37,04240 claims |
| Astellas Pharma US IncMyrbetriq | $103 | $8,91215 claims |
| AbbVieSynthroid | $515 | $1,20225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 808 internal medicine providers in Rhode Island.
Other internal medicine in Wakefield
- David FriedEast Greenwich$37.2M
- Gregory AllenCranston$12.2M
- Kathleen GordonJohnston$1.1M
- William BeliveauJohnson$962K
- Scott WilsonCumberland$907K
- Aaron SamuelsProvidence$751K
- Frank D'alessandroLincoln$541K
- Andrew HsuProvidence$409K
- Heinrich ElinzanoProvidence$396K
- Ari PelcovitsProvidence$179K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.